Thymic Carcinoma - Pipeline Review, H2 2016

  • ID: 3960452
  • Drug Pipelines
  • 87 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Novartis AG
  • Onxeo SA
  • Tiziana Life Sciences Plc
  • MORE
Thymic Carcinoma - Pipeline Review, H2 2016

Thymic Carcinoma - Pipeline Review, H2 2016, provides an overview of the Thymic Carcinoma (Oncology) pipeline landscape.

Thymus cancers are uncommon cancers that start in the thymus. Symptoms include shortness of breath, cough, chest pain, trouble swallowing, loss of appetite, headaches and weight loss. Predisposing factor include age and other autoimmune diseases such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia.

Report Highlights:

Thymic Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thymic Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thymic Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thymic Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Thymic Carcinoma.

Thymic Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thymic Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Thymic Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thymic Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thymic Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thymic Carcinoma (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thymic Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thymic Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Merck & Co., Inc.
  • Novartis AG
  • Onxeo SA
  • Tiziana Life Sciences Plc
  • MORE
Introduction

Thymic Carcinoma Overview

Therapeutics Development

Pipeline Products for Thymic Carcinoma - Overview

Pipeline Products for Thymic Carcinoma - Comparative Analysis

Thymic Carcinoma - Therapeutics under Development by Companies

Thymic Carcinoma - Therapeutics under Investigation by Universities/Institutes

Thymic Carcinoma - Pipeline Products Glance

Clinical Stage Products

Thymic Carcinoma - Products under Development by Companies

Thymic Carcinoma - Products under Investigation by Universities/Institutes

Thymic Carcinoma - Companies Involved in Therapeutics Development

Merck & Co., Inc.

Novartis AG

Onxeo SA

Sumitomo Dainippon Pharma Co., Ltd.

Taiwan Liposome Company, Ltd.

Tiziana Life Sciences Plc

Thymic Carcinoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

amrubicin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLC-388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thymic Carcinoma - Product Development Milestones

Featured News & Press Releases

Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014

May 14, 2014: Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO

List of Tables

Number of Products under Development for Thymic Carcinoma, H2 2016

Number of Products under Development for Thymic Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Thymic Carcinoma - Pipeline by Merck & Co., Inc., H2 2016

Thymic Carcinoma - Pipeline by Novartis AG, H2 2016

Thymic Carcinoma - Pipeline by Onxeo SA, H2 2016

Thymic Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016

Thymic Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016

Thymic Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

List of Figures

Number of Products under Development for Thymic Carcinoma, H2 2016

Number of Products under Development for Thymic Carcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Merck & Co., Inc.
- Novartis AG
- Onxeo SA
- Sumitomo Dainippon Pharma Co., Ltd.
- Taiwan Liposome Company, Ltd.
- Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll